Frazier Life Sciences Management, L.P. Trevi Therapeutics, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.86 Billion
- Q3 2024
A detailed history of Frazier Life Sciences Management, L.P. transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 7,381,090 shares of TRVI stock, worth $28.9 Million. This represents 1.33% of its overall portfolio holdings.
Number of Shares
7,381,090
Previous 7,381,090
-0.0%
Holding current value
$28.9 Million
Previous $22 Million
12.08%
% of portfolio
1.33%
Previous 1.3%
Shares
5 transactions
Others Institutions Holding TRVI
# of Institutions
95Shares Held
57.1MCall Options Held
136KPut Options Held
5.4K-
Nea Management Company, LLC Timonium, MD11.4MShares$44.6 Million2.9% of portfolio
-
Rubric Capital Management LP New York, NY5.03MShares$19.7 Million0.47% of portfolio
-
Viking Global Investors LP4.4MShares$17.2 Million0.06% of portfolio
-
Vr Adviser, LLC New York, NY3.42MShares$13.4 Million1.18% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.26MShares$12.8 Million0.0% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $229M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...